A Study to Evaluate the Effect of Dupilumab on Exercise Capacity in Adult Patients With Asthma

Exclusion Criteria

• •Body mass index \>35 kg/m2 at screening
• •Current smoking, vaping or tobacco chewing or cessation of any of these within 6 months prior to randomization, or \>10 pack years smoking history
• •Patients who require supplemental oxygen at screening
• •Clinically significant cardiac disease as described in the protocol
• •Uncontrolled hypertension at screening or baseline
• •Participation in exercise or physical rehabilitation program within last 6 months prior to screening or planned during the study
• •Previous use of dupilumab
• •Anti-IgE therapy (eg, omalizumab \[Xolair®\]) within 130 days prior to visit 1 or any other biologic therapy (including anti-IL5, anti-IL-5R, anti-IL4Rα, anti-IL-13 mAb) or systemic immunosuppressant (eg, methotrexate, any anti-tumor necrosis factor mAbs, Janus kinase inhibitors, B- and/or T-cell targeted immunosuppressive therapies) to treat inflammatory disease or autoimmune disease (eg, rheumatoid arthritis, inflammatory bowel disease, primary biliary cirrhosis, systemic lupus erythematosus, multiple sclerosis) and other diseases, within 3 months or 5 half-lives prior to screening, whichever is longer
• •Exposure to another investigative drug (monoclonal antibodies as well as small molecules) within a period prior to screening, of \<3 months or \<5 half-lives (whichever is longer)
• •Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study
• •Women of childbearing potential (WOCBP)\* who are unwilling to practice highly effective contraception prior to the initial dose/start of the first treatment, during the study, and for at least 12 weeks after the last dose